IL4I1 (32), a secreted L-phenylalanine oxidase, has previously been shown to play a role in B and T cell adaptive immune responses, activate the aryl hydrocarbon receptor, be increased in cancer patients, and be involved in resistance to immune checkpoint inhibitor therapy in cancer patients (33). This evidence concerns the gene AHR and cancer.